Gene Silencing and Regulation - Clinical Research Informer

Laverock Therapeutics raises £13.5m to accelerate gene silencing platform

BioPharma Reporter

OCTOBER 2, 2023

Laverock Therapeutics, the gene editing-induced gene silencing platform for human therapeutic applications, has expanded its seed funding round to Â13.5 million.

Gene Silencing

Gene Silencing Gene Gene Editing Regulation

Methylation of tRNA-derived fragments regulates gene-silencing activity in bladder cancer

Scienmag

MAY 9, 2022

and colleagues have described a novel form of gene regulation that is altered in bladder cancer, leading to the boosting of a gene pathway that helps the cancer cells survive during rapid growth. BIRMINGHAM, Ala. Anindya Dutta, MBBS, Ph.D., Credit: UAB BIRMINGHAM, Ala. Anindya Dutta, MBBS, Ph.D.,

Gene Silencing

Gene Silencing Regulation Gene

Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit

pharmaphorum

JANUARY 6, 2021

Two years after starting to work together, Novo Nordisk and Dicerna have selected the first candidate from a joint project to find new, gene-silencing drugs for liver-related cardiometabolic diseases. The post Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit appeared first on.

Gene Silencing

Gene Silencing Gene RNA Contract Manufacturing

Novo Nordisk snaps up RNAi partner Dicerna in $3.3bn takeover deal

pharmaphorum

NOVEMBER 18, 2021

Danish drugmaker Novo Nordisk must like what it has seen in its two-year-old alliance with gene-silencing specialist Dicerna Pharma – it has just agreed to acquire the biotech for $3.3 billion in cash.

Gene Silencing

Gene Silencing RNA Protein Gene

High hopes as Inventiva takes NASH contender into phase 3

pharmaphorum

JANUARY 6, 2021

The regulator said it wanted more long-term safety and efficacy data from the REGENERATE study before making a final decision on the drug, which had been expected to be the first entrant into a likely multi-billion dollar market niche. The post High hopes as Inventiva takes NASH contender into phase 3 appeared first on.

Gene Silencing

Gene Silencing Regulation Pharma Companies Doctors

Cash round sets up trial of InteRNA’s microRNA for cancer

pharmaphorum

FEBRUARY 9, 2021

InteRNA is focusing on the development of gene-silencing drugs based on microRNA, naturally occurring, non-coding strands of RNA that are thought to regulate gene expression in cells.

Trials

Trials Gene Silencing RNA Gene Expression

FDA approves Alnylam’s ultra-rare disease drug Oxlumo

pharmaphorum

NOVEMBER 24, 2020

The FDA has approved Alnylam’s gene silencing drug Oxlumo, the first treatment for primary hyperoxaluria type 1 (PH1), an ultra-rare and life-threatening genetic disorder. The Swiss pharma’s bet looks to have paid off as inclisiran is likely to be approved in Europe in the coming weeks after backing from CHMP regulators last month.

FDA Approval

FDA Approval Gene Silencing Drugs RNA

uniQure signs license deal for Apic Bio’s gene therapy for SOD1-ALS

Pharmaceutical Technology

JANUARY 31, 2023

Under the terms of the deal, uniQure will obtain the worldwide rights to develop and market the clinical stage gene therapy, APB-102. uniQure stated that the license of APB-102 further strengthens its gene therapies pipeline developed for the treatment of neurological disorders as well as miRNA-based gene silencing programmes.

Gene Therapy

Gene Therapy Licensing Licensing Gene

MHRA gives Alnylam ‘innovation passport’ for hypertension drug zilebesiran

pharmaphorum

JUNE 8, 2022

The UK medicines regulator has awarded Alnylam’s RNAi-based therapy zilebesiran for hypertension an ‘innovation passport ‘, a designation designed to speed up NHS access to promising new medicines.

Gene Silencing

Gene Silencing Drugs Medicine Regulation

Epigenetic Editing with CRISPR Might Be Easier Than We Thought

XTalks

MAY 4, 2021

Researchers at the University of California San Francisco (UCSF) and the Whitehead Institute have developed a novel CRISPR-based tool called “CRISPRoff” that can switch off genes in human cells through epigenetic editing without altering the genetic sequence itself.

DNA

DNA Gene Gene Silencing Genome

Using CRISPR to Edit the Epigenome Might Be Easier Than We Thought

XTalks

MAY 4, 2021

Researchers at the University of California San Francisco (UCSF) and the Whitehead Institute have developed a novel CRISPR-based tool called “CRISPRoff” that can switch off genes in human cells without editing the genetic sequence itself. These modifications regulate gene expression without altering the sequence or structure of DNA.

DNA

DNA Gene Gene Silencing Genome

Two biotechs target dry eye disease after Novartis’ Xiidra problems

pharmaphorum

MARCH 4, 2021

But with Novartis failing to convince European regulators about the merits of Xiidra last year, and Allergan’s ageing Restasis potentially facing generic competition, there’s a lot to play for and two biotechs are aiming to disrupt the market. Novartis paid Takeda $3.4

Gene Silencing

Gene Silencing FDA Approval Trials Marketing

World RNA Day: What impact RNA it had on drug discovery?

Drug Discovery World

AUGUST 1, 2023

The NIH states: “This natural mechanism for sequence-specific gene silencing promises to revolutionise experimental biology and may have important practical applications in functional genomics, therapeutic intervention, agriculture and other areas.”

RNA

RNA Drugs Gene Silencing Vaccination

RNA Therapeutics: A Novel Approach to Treating Diseases

Roots Analysis

OCTOBER 22, 2023

RNA interference (RNAi) Therapeutics : Fundamentally, RNAi is a natural process of post-transcriptional gene silencing, involving short strands of nucleic acids. Cells use this process to silence and / or inhibit gene expression, via targeted degradation of specific (unwanted) mRNA molecules.

RNA

RNA Protein Genetics Gene Expression

Clinical Research Informer

Laverock Therapeutics raises £13.5m to accelerate gene silencing platform

Methylation of tRNA-derived fragments regulates gene-silencing activity in bladder cancer

Trending Sources

Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit

Novo Nordisk snaps up RNAi partner Dicerna in $3.3bn takeover deal

High hopes as Inventiva takes NASH contender into phase 3

Cash round sets up trial of InteRNA’s microRNA for cancer

FDA approves Alnylam’s ultra-rare disease drug Oxlumo

uniQure signs license deal for Apic Bio’s gene therapy for SOD1-ALS

MHRA gives Alnylam ‘innovation passport’ for hypertension drug zilebesiran

Epigenetic Editing with CRISPR Might Be Easier Than We Thought

Using CRISPR to Edit the Epigenome Might Be Easier Than We Thought

Two biotechs target dry eye disease after Novartis’ Xiidra problems

World RNA Day: What impact RNA it had on drug discovery?

RNA Therapeutics: A Novel Approach to Treating Diseases

Stay Connected